| (USD) | Sep 2022 | Q/Q |
|---|---|---|
| Revenue | 151.9MM | +1% |
| Gross Profit | 83.4MM | +5% |
| Cost Of Revenue | 68.5MM | -4% |
| Operating Income | 25MM | -567% |
| Operating Expenses | 58.4MM | - |
| Net Income | 14.5MM | -123% |
| R&D | 23.7MM | +4% |
| G&A | 32.5MM | -46% |
| Interest Expense | 1.2MM | -34% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
CHICAGO, April 09, 2024--Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book, a healthcare-centric market research and public opinion research and consulting company, has ranked Practice Fusion first for Ambulatory EHR PM Family Practice and Ambulatory EHR PM Primary Care General Practice within its 2024 Top Client/User-Rated Electronic Health Records & Practice Management Solutions report.
CHICAGO, March 14, 2024--Veradigm Inc. (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions announced today that Dr. Yin Ho, Veradigm Interim Chief Executive Officer and board member, Lee Westerfield, Interim Chief Financial Officer, and Will Manidis Co-Founder of ScienceIO will participate in a fireside chat at the KeyBanc Capital Markets Life Science & MedTech Investor Forum on Tuesday, March 19th, 2024 at 12:00 PM EDT.
CHICAGO, March 13, 2024--Veradigm Inc. (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today it has reaffirmed the estimated, unaudited ranges for fiscal 2023 of GAAP Revenue, Adjusted EBITDA, and Non-GAAP diluted earnings per share that it provided on January 10, 2024, in the Company’s Form 8-K filed on January 10, 2024, and initially reaffirmed on February 27, 2024.
CHICAGO, March 04, 2024--Veradigm Inc. (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions announced today that Dr. Yin Ho, Veradigm interim Chief Executive Officer and board member, Lee Westerfield, interim Chief Financial Officer, and Will Manidis, Senior Vice President and the former CEO of ScienceIO, will participate in a fireside chat and investor Q&A, as well as meet with investor attendees during the Barclays 26th Annual Global Healthcare Conference on Wednesda
CHICAGO, March 04, 2024--Veradigm Inc. (OTCMKTS: MDRX) (the "Company"), a leading provider of healthcare data and technology products and solutions, today announced that it has completed its acquisition of ScienceIO, a leading AI platform and foundation model provider for the healthcare ecosystem.
Sprinklr Inc. (NYSE:CXM) will replace Veradigm Inc. (NASD:MDRX) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, March 4. Veradigm will be suspended from the Nasdaq Stock Market on February 29 due to non-compliance with NASDAQ listing rules and is no longer eligible for continued inclusion in the S&P SmallCap 600.
CHICAGO, February 28, 2024--Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology products and solutions, announced today that, as expected, it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Nasdaq Hearings Panel (the "Panel") has determined to delist the common stock of the Company from Nasdaq (the "Decision"). The Decision indicates that the Company remains noncompliant with Nasdaq Listing Rule 5250(c)(1) and Nasdaq Listing Rule 5
CHICAGO, February 28, 2024--Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology products and solutions, today announced that Dr. Yin Ho, Veradigm interim Chief Executive Officer, and Lee Westerfield, interim Chief Financial Officer, will present at the TD Cowen Annual Health Care Conference on Monday, March 4, 2024, at 9:50 AM Eastern Time.
Veradigm to Bolster Healthcare AI Platform with $140 Million ScienceIO Purchase
CHICAGO, February 27, 2024--Veradigm Inc. (NASDAQ: MDRX) (the "Company"), a leading provider of healthcare data and technology products and solutions, today announced that it has signed a definitive agreement to acquire ScienceIO. The transaction has been unanimously approved by the Veradigm Board of Directors and is expected to close as promptly as practicable following the satisfaction of customary closing conditions.